A clinical trial is being planned to evaluate a groundbreaking intervention for patients with SYNGAP1-related disorder. This trial will mark the first time the intervention is tested in humans, aiming to determine its effectiveness in modifying the course of the disease. SYNGAP1-related disorder affects approximately [insert number] individuals worldwide and currently lacks effective treatment options. The trial holds promise for potentially improving the quality of life for patients with this rare genetic disorder.